Merck Emend Medicare National Coverage Decision Expected By April 2005
This article was originally published in The Pink Sheet Daily
Executive Summary
CMS is accepting public comment on whether aprepitant is a “full replacement” for other anti-emetic treatments in response to an “internally generated” coverage determination request.
You may also be interested in...
Merck's Emend To Be Covered Under Part B In Draft CMS Coverage Decision
The anti-emetic would be covered by Medicare Part B when used in combination with a 5-HT3 antagonist and dexamethasone in patients refractory to standard treatments, CMS says. Other uses of Emend would be covered under Part D beginning in 2006.
Merck's Emend To Be Covered Under Part B In Draft CMS Coverage Decision
The anti-emetic would be covered by Medicare Part B when used in combination with a 5-HT3 antagonist and dexamethasone in patients refractory to standard treatments, CMS says. Other uses of Emend would be covered under Part D beginning in 2006.
Merck Emend Coverage Decision Will Not Affect Aloxi, MGI Says
The Centers for Medicare & Medicaid Services' initiation of a national coverage determination process for Merck' anti-emetic Emend will have no impact on MGI Pharma's Aloxi, MGI CEO Lonnie Moulder said during a July 14 conference call